| Overview |
| bs-0522R-Cy7 |
| CD45 Polyclonal Antibody, Cy7 Conjugated |
| WB, FCM, IF(IHC-P), IF(ICC) |
| The antibody is predicted to work with Mouse and Rat samples, but with decreased sensitivity compared to human samples. |
| Human |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CD45 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 5788 |
| P08575 |
| Cell membrane |
| LCA; LY5; B220; CD45; L-CA; T2; CD45R; GP18; Receptor-type tyrosine-protein phosphatase C; Leukocyte common antigen; PTPRC |
| Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity (By similarity). |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz